Centauri Therapeutics closes £ 24 million Series A investment round
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
The recommendation has been sent to the DCGI for approval
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
It will open new frontier for south-to-south collaboration and innovation transfer
Subscribe To Our Newsletter & Stay Updated